WO2000057787A3 - Method for localization of blood clots - Google Patents

Method for localization of blood clots Download PDF

Info

Publication number
WO2000057787A3
WO2000057787A3 PCT/US2000/007891 US0007891W WO0057787A3 WO 2000057787 A3 WO2000057787 A3 WO 2000057787A3 US 0007891 W US0007891 W US 0007891W WO 0057787 A3 WO0057787 A3 WO 0057787A3
Authority
WO
WIPO (PCT)
Prior art keywords
array
dimensional
line
localization
blood clots
Prior art date
Application number
PCT/US2000/007891
Other languages
French (fr)
Other versions
WO2000057787A2 (en
Inventor
Joel Lazewatsky
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Priority to AU40278/00A priority Critical patent/AU4027800A/en
Priority to CA002364753A priority patent/CA2364753A1/en
Priority to BR0010517-1A priority patent/BR0010517A/en
Priority to IL14513000A priority patent/IL145130A0/en
Publication of WO2000057787A2 publication Critical patent/WO2000057787A2/en
Publication of WO2000057787A3 publication Critical patent/WO2000057787A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Image Processing (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A method wherein a radiolabelled compound is localized at a thrombus. Two-dimensional images, representing a physical property associated with the radiolabelled thrombus, are acquired and assembled into a three-dimensional matrix of data. The three-dimensional matrix of data is then scanned along an array of parallel lines to determine a maximum value along each line. The maximum value along each line is then assigned to a pixel in a two-dimensional array, where the relative position of the pixel in the two-dimensional array corresponds to the relative position of the line in the array of parallel lines.
PCT/US2000/007891 1999-03-26 2000-03-24 Method for localization of blood clots WO2000057787A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU40278/00A AU4027800A (en) 1999-03-26 2000-03-24 Method for localization of blood clots
CA002364753A CA2364753A1 (en) 1999-03-26 2000-03-24 Method for localization of blood clots
BR0010517-1A BR0010517A (en) 1999-03-26 2000-03-24 Imaging methods of a thrombus, pulmonary embolus, arterial thrombus and coronary thrombus
IL14513000A IL145130A0 (en) 1999-03-26 2000-03-24 Method for localization of blood clots

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12635999P 1999-03-26 1999-03-26
US60/126,359 1999-03-26

Publications (2)

Publication Number Publication Date
WO2000057787A2 WO2000057787A2 (en) 2000-10-05
WO2000057787A3 true WO2000057787A3 (en) 2001-02-22

Family

ID=22424397

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007891 WO2000057787A2 (en) 1999-03-26 2000-03-24 Method for localization of blood clots

Country Status (5)

Country Link
AU (1) AU4027800A (en)
BR (1) BR0010517A (en)
CA (1) CA2364753A1 (en)
IL (1) IL145130A0 (en)
WO (1) WO2000057787A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022494A1 (en) * 1993-03-30 1994-10-13 The Du Pont Merck Pharmaceutical Company RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS
WO1996031243A1 (en) * 1995-04-03 1996-10-10 The Du Pont Merck Pharmaceutical Company Ternary radiopharmaceutical complexes
WO1996040637A1 (en) * 1995-06-07 1996-12-19 The Du Pont Merck Pharmaceutical Company Stable reagents for the preparation of radiopharmaceuticals

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022494A1 (en) * 1993-03-30 1994-10-13 The Du Pont Merck Pharmaceutical Company RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS
WO1996031243A1 (en) * 1995-04-03 1996-10-10 The Du Pont Merck Pharmaceutical Company Ternary radiopharmaceutical complexes
WO1996040637A1 (en) * 1995-06-07 1996-12-19 The Du Pont Merck Pharmaceutical Company Stable reagents for the preparation of radiopharmaceuticals

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BARRETT JOHN A ET AL: "Biological evaluation of thrombus imaging agents utilizing water soluble phosphines and tricine as coligands when used to label a hydrazinonicotinamide-modified cyclic glycoprotein IIb/IIIa receptor antagonist with 99mTc.", BIOCONJUGATE CHEMISTRY, vol. 8, no. 2, 1997, pages 155 - 160, XP002154879, ISSN: 1043-1802 *
EDWARDS D S ET AL: "NEW AND VERSATILE TERNARY LIGAND SYSTEM FOR TECHNETIUM RADIOPHARMACEUTICALS: WATER SOLUBLE PHOSPHINES AND TRICINE AS COLIGANDS IN LABELING A HYDRAZINONICOTINAMIDE-MODIFIED CYCLIC GLYCOPROTEIN IIB/IIIA RECEPTOR ANTAGONIST WITH 99MTC", BIOCONJUGATE CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 8, no. 2, 1 March 1997 (1997-03-01), pages 146 - 154, XP000682494, ISSN: 1043-1802 *
HARRIS T D ET AL: "Tc-99m-labeled fibrinogen receptor antagonists: design and synthesis of cyclic RGD peptides for the detection of thrombi", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 6, no. 15, 6 August 1996 (1996-08-06), pages 1741 - 1746, XP004135594, ISSN: 0960-894X *
HOM R K ET AL: "Technetium-99m-Labeled Receptor-Specific Small-Molecule Radiopharmaceuticals: Recent Developments and Encouraging Results", NUCLEAR MEDICINE AND BIOLOGY,US,ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, vol. 24, no. 6, 1 August 1997 (1997-08-01), pages 485 - 498, XP004089519, ISSN: 0969-8051 *
LIU SHUANG ET AL: "Labeling a hydrazino nicotinamide-modified cyclic IIb/IIIa receptor antagonist with 99mTc using aminocarboxylates as coligands.", BIOCONJUGATE CHEMISTRY, vol. 7, no. 1, 1996, pages 63 - 71, XP002154880, ISSN: 1043-1802 *
RAJOPADHYE M ET AL: "Synthesis, evaluation and Tc-99m complexation of a hydrazinonicotinyl conjugate of a gp IIb/IIIa antagonist cyclic peptide for the detection of deep vein thrombosis", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 7, no. 8, 22 April 1997 (1997-04-22), pages 955 - 960, XP004136163, ISSN: 0960-894X *

Also Published As

Publication number Publication date
AU4027800A (en) 2000-10-16
CA2364753A1 (en) 2000-10-05
WO2000057787A2 (en) 2000-10-05
IL145130A0 (en) 2002-06-30
BR0010517A (en) 2002-01-08

Similar Documents

Publication Publication Date Title
AU6340698A (en) Ultrasonic probe, system and method for two-dimensional imaging or dimensional reconstruction
WO2001033511A3 (en) System and method for producing a three-dimensional model
AU3901800A (en) System and method for performing a three-dimensional virtual segmentation and examination
ITMI20000897A0 (en) SYSTEM AND METHOD FOR PROVIDING VARIABLE ULTRASOUND ANALYSIS IN A AFTER STORAGE MANNER.
AU8024500A (en) Modality fusion for object tracking with training system and method
WO2003096883A3 (en) Combined diagnostic and therapeutic ultrasound system
AU2002211331A1 (en) System and method for performing a three-dimensional virtual examination of objects, such as internal organs
AU5112898A (en) System, employing three-dimensional ultrasonographic imaging, for assisting in guiding and placing medical instruments
AU2115600A (en) 3d/4d ultrasound imaging system
IL134484A0 (en) Automated segmentation method for 3-dimensional ultrasound
AU6261898A (en) Catheter-mounted, phased-array ultrasound transducer with improved imaging
AU2003259524A1 (en) System and method for visualizing scene shift in ultrasound scan sequence
AU3901700A (en) System and method for performing a three-dimensional virtual examination, navigation and visualization
AU7466896A (en) Phased array ultrasound system and method for cardiac ablation
AU2001247311A1 (en) A system and method for obtaining, processing and evaluating patient information for diagnosing disease and selecting treatment
AU7440300A (en) Seismic data acquisition and processing method
AU2001238645A1 (en) Ultrasonic imaging system and associated method
AU2001285477A1 (en) System and method for complexity analysis-based cardiac tachyarrhythmia detection
AU5209599A (en) System and method for optimizing medical diagnosis, procedures and claims using a structured search space
EP0945060A3 (en) Method and system for monitoring animals
AU1761901A (en) System and method for skin lesion examination using multi-spectral, multi-sourcetransillumination
AU3342400A (en) Method for combining physical objects using polar coordinate statistical analysis
HUP0201304A2 (en) Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations
WO2000057787A3 (en) Method for localization of blood clots
WO2002083892A3 (en) Mutants of desoxycytidine kinase having extended enzymatic activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN CZ EE HU IL IN JP KR LT LV MX NO NZ PL RO SG SI SK TR UA VN ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN CZ EE HU IL IN JP KR LT LV MX NO NZ PL RO SG SI SK TR UA VN ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 200106361

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 513365

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2364753

Country of ref document: CA

Ref country code: CA

Ref document number: 2364753

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 145130

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2001-3360

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV2001-3360

Country of ref document: CZ

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP